Study of QL1706 and lenvatinib before liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two drugs, QL1706 (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks blood supply to tumors), given before surgery can help shrink liver cancer and lower the chance of it coming back. It may be an option for people with certain types of liver cancer that are considered high-risk for recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatocellular carcinoma (the most common type of liver cancer) at a stage that can be treated with surgery, but you haven't had it yet.
- You are between 18 and 75 years old.
- You have not received any previous systemic treatment for your liver cancer, and you have never had surgery for this cancer.
- You have at least one tumor that can be measured on a scan.
- Your liver, kidney, and heart function are good enough, and your blood counts are within a certain range.
- You are willing to use effective birth control during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests a new drug called QL1706 for people with advanced liver cancer that has worsened after a previous immunotherapy treatment. The goal is to see if it can help slow down the cancer.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.